Daré Bioscience (DARE) investor relations material

Executive summary

• Special meeting scheduled to approve potential future issuance of common stock upon exercise of outstanding warrants and to approve adjournment if more votes are needed for Proposal 1.

• Meeting will be held virtually, allowing global participation and cost savings.

• Only stockholders of record as of the record date are entitled to vote; each share has one vote per proposal.

Voting matters and shareholder proposals

• Proposal 1 seeks approval for issuance of up to 8,934,345 shares upon exercise of warrants issued in August 2026 financing, as required by Nasdaq rules.

• Proposal 2 seeks approval to adjourn the meeting if more proxies are needed to pass Proposal 1.

• Board recommends voting FOR both proposals.

• No dissenters' or appraisal rights are available for these matters.

• Stockholder proposals for the 2027 annual meeting must be submitted between February 11 and March 13, 2027.

Board of directors and corporate governance

• None of the directors, officers, or their affiliates participated in the August 2026 financing or hold the related warrants.

• Proxy solicitation costs are covered by the company; directors and employees may solicit proxies without extra compensation.